Gloved hand placing a sample vial into laboratory testing equipment
Global science-led healthcare

Advancing global health through rigorous science

Anhui Kangrong Pharmaceuticals Co., Ltd. was established in December 2021. It is a pharmaceutical company integrating the research and development, manufacturing, and sales of chemical drug formulations. Located in the High-Tech Industrial Development Zone of Bozhou City, Anhui Province, China. The company’s product portfolio covers a variety of dosage forms, including eye drops, oral drops, and oral solutions.

Countries served
40+

Countries served

Annual R&D investment
$1.9B

Annual R&D investment

Years of science
60

Years of science

Our products

Featured medicines across the areas that matter most

View all products
Kangrong Pharmaceutical Lacosamide Oral Solution 200mlOral Solutions & Drops

Oral Solutions & Drops

Lacosamide Oral Solution

Lacosamide

View product details
Researchers working at laboratory instruments and computers

Research & development

Turning breakthrough science into real medicine

Our scientists combine data-driven discovery, translational biology, and global clinical expertise to move candidates from the lab to the clinic with speed and integrity.

Discovery
120+

active research programs

Preclinical
48

candidates in development

Clinical
31

trials across phases I–III

Filed / Approved
9

new medicines since 2022

Manufacturing & supply

Reliable supply the world can depend on

From sterile biologics to essential medicines, our global network is built for quality, resilience, and responsible production.

Precision at scale

22 manufacturing sites producing over 40 billion doses each year.

Uncompromised quality

Every batch meets GMP standards with full end-to-end traceability.

Resilient supply

A distributed network engineered to keep medicines available worldwide.

Sustainable operations

Carbon-neutral targets and water stewardship across all facilities.

Newsroom

Latest from Kangrong Pharmaceuticals

All news
Team Photo

5 Aug 2026

Strengthening University–Industry Collaboration: Bozhou University Pharmacy Faculty and Students Visit Our Company

To further strengthen university–industry collaboration, promote the integration of education and industry, support the development of pharmaceutical professionals, and provide a platform connecting academic learning with industry practice, approximately 160 faculty members and students from the Pharmacy Program of Bozhou University visited our company in two groups on May 28 and June 23, 2026. To ensure that the visits were conducted safely, efficiently, and in an orderly manner, our Human Resources & Administration Department, Production Department, Quality Department, and other relevant teams worked closely together to make comprehensive preparations in advance. These included safety inspections of the facility, planning of visitor routes, coordination of guides, and access control for clean production areas. During the visits, department representatives provided detailed introductions to our production safety management systems, modern pharmaceutical manufacturing processes, and Quality Control (QC) procedures. Faculty members and students toured key areas of the company, including the clean production workshops and quality control laboratories, gaining first-hand insight into the standardized, regulated, and highly refined operations of a modern pharmaceutical company. Through this on-site learning experience, the visiting faculty and students gained a more comprehensive understanding of the entire pharmaceutical manufacturing process and the stringent quality and safety requirements of the pharmaceutical industry. The visit also helped reinforce their theoretical knowledge while providing a closer look at our rigorous quality management system and standardized corporate operations. At the same time, this university–industry exchange provided an opportunity to showcase our professional corporate culture, well-managed production environment, and established talent development system. It further strengthened the foundation for cooperation between the university and our company while enhancing our corporate presence and industry engagement. Going forward, Kangrong Pharmaceutical will continue to deepen university–industry collaboration in talent development and regularly carry out cooperative programs such as student visits, industry orientation programs, internships, and employment-related practical training. We remain committed to fulfilling our corporate social responsibility and contributing to the development of highly skilled professionals for the pharmaceutical industry.

Read more
Great News! Kangrong Pharmaceutical’s Tigecycline for Injection Approved

2 Jul 2026

Great News! Kangrong Pharmaceutical’s Tigecycline for Injection Approved

Beijing Rongying Pharmaceutical Technology Co., Ltd. has received the Drug Registration Certificate for Tigecycline for Injection issued by the relevant regulatory authority, with the drug approval number NMPA Approval No. H20265029 . Rongying Pharmaceutical is the R&D subsidiary of Kangrong Pharmaceutical. Tigecycline for Injection , available in a 50 mg strength, is indicated for the treatment of patients aged 18 years and older with complicated intra-abdominal infections caused by susceptible bacteria, including Citrobacter freundii , Escherichia coli , and Bacteroides fragilis ; complicated skin and soft tissue infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA); and community-acquired bacterial pneumonia.

Read more
Great News! Kangrong Pharmaceutical’s Levofloxacin Eye Drops Approved

15 Jun 2026

Great News! Kangrong Pharmaceutical’s Levofloxacin Eye Drops Approved

Kangrong Pharmaceutical has received the Drug Registration Certificate for Levofloxacin Eye Drops issued by the relevant regulatory authority, with the drug approval number NMPA Approval No. H20264702 . Levofloxacin Eye Drops , strength: 0.488% (5 mL: 24.4 mg) (calculated as C₁₈H₂₀FN₃O₄), are primarily indicated for the treatment of blepharitis, hordeolum, dacryocystitis, conjunctivitis, meibomianitis, and keratitis, as well as for antimicrobial prophylaxis during the perioperative period in ophthalmic surgery.

Read more

Partner with us

Let's advance the next generation of medicine together

We collaborate with academic institutions, biotech innovators, and healthcare systems to bring transformative science to patients faster. Tell us where you’d like to begin.